Chronic refractory cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialities: Pulmonology, Allergy and Immunology, Digestive Health and Otorhinolaryngology.
The diagnosis of Chronic Refractory Cough is either done by primary or secondary assessment. The initial assessment for protracted or chronic cough is intended to characterize the condition based on history, to elicit any alarm symptoms or findings that may indicate a serious underlying disease, and to identify whether there is a specific disease present that is associated with chronic cough. A second stage investigation is considered to further characterize the condition of the disease. These include nasendoscopy and 24 hour pH monitoring.
There are currently no approved therapies for Chronic Refractory Cough. However, various off-label and over-the-counter medications are being used to treat the condition. These include neuromodulators, proton pump inhibitors, inhaled corticosteroids(ICs) and others.
Get FREE sample copy at:
The Chronic Refractory Cough market report also covers emerging drugs, current treatment practices, Chronic Refractory Cough market share of the individual therapies, current and forecasted Chronic Refractory Cough Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chronic Refractory Cough treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Chronic Refractory Cough Market Key Facts
The total prevalent population of Chronic Cough in the 7 major markets was estimated to be 84,854,266 in 2020.
The diagnosed prevalent population of CRC in the 7 MM is expected to increase at a CAGR of 0.48% during the forecast period.
In the EU5 countries, the prevalent population of Chronic Cough was maximum in France with 8,799,771 cases, followed by the United Kingdom with 8,682,007 cases in 2020. While Spain accounted for the lowest diagnosed prevalent population of the indication with 5,708,813 cases in 2020.
As per Delvelnsight’s analysis, Japan had 683,935 diagnosed prevalent cases of CRC in 2020.
In the United States, the total prevalent cases of Chronic Cough consisted of 10,805,114 males and 29,213,828 females in 2020.
Key Benefits of Chronic Refractory Cough Market Report
Chronic Refractory Cough market report provides an in-depth analysis of Chronic Refractory Cough Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Chronic Refractory Cough market report will help in developing business strategies by understanding the Chronic Refractory Cough Market trends & developments, key players and future market competition that will shape and drive the Chronic Refractory Cough market in the upcoming years.
The Chronic Refractory Cough market report covers Chronic Refractory Cough current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Chronic Refractory Cough market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Chronic Refractory Cough Market
Chronic Refractory Cough market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The Chronic Refractory Cough market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Refractory Cough market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Chronic Refractory Cough market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Chronic Refractory Cough Epidemiology
The Chronic Refractory Cough epidemiology section covers insights about historical and current Chronic Refractory Cough patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Refractory Cough Drugs Uptake and Key Market Players
The Chronic Refractory Cough Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to get launched in the market during the study period. The analysis covers Chronic Refractory Cough market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Chronic Refractory Cough market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies.
The key companies in the Chronic Refractory Cough market include:
And many others.
Chronic Refractory Cough therapies covered in the report include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Refractory Cough Competitive Intelligence Analysis
4. Chronic Refractory Cough Market Overview at a Glance
5. Chronic Refractory Cough Disease Background and Overview
6. Chronic Refractory Cough Patient Journey
7. Chronic Refractory Cough Epidemiology and Patient Population
8. Chronic Refractory Cough Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Refractory Cough Unmet Needs
10. Key Endpoints of Chronic Refractory Cough Treatment
11. Chronic Refractory Cough Marketed Products
12. Chronic Refractory Cough Emerging Therapies
13. Chronic Refractory Cough Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Refractory Cough Market Outlook (7 major markets)
16. Chronic Refractory Cough Access and Reimbursement Overview
17. KOL Views on the Chronic Refractory Cough Market.
18. Chronic Refractory Cough Market Drivers
19. Chronic Refractory Cough Market Barriers
21. DelveInsight Capabilities
Chronic Refractory Cough Epidemiology Forecast
DelveInsight’s Chronic Refractory Cough – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Chronic Refractory Cough in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Related Blog –
Chronic Refractory Cough Treatment Market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States